Stay updated with breaking news from Patient Centered. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Huadong Medicine is granted from AKSO Biopharmaceutical an exclusive right to develop and commercialize AB002 in the Asia Pacific Ex-Japan region for solid tumors; AKSO Biopharmaceutical to receive up
/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...
/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...
Researchers review the risks and benefits of deprescribing from antipsychotic drugs and advocate for a patient-centered approach to tapering.
Sirnaomics Announces Acceptance of Investigational New Drug Application by China NMPA for Global Multicenter Phase 2b Trial of STP705 Treatment for Skin Squamous Cell Carcinoma News provided by Share this article Share this article GAITHERSBURG, Md. and SUZHOU BIOBAY, China, June 16, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases, and other unmet clinical indications, today announced that the China National Medical Product Administration (NMPA) has accepted its Investigational ...